Antimicrobial therapy for acute cholecystitis: Tokyo Guidelines.

Area of Science:

• Gastroenterology
• Infectious Diseases
• Pharmacology

Background:

• Acute cholecystitis presents a spectrum of severity, from mild inflammation to severe biliary peritonitis.
• Microbial etiology is central to acute cholecystitis, necessitating identification of aerobic and anaerobic organisms.

Purpose of the Study:

• To outline optimal antimicrobial strategies for acute cholecystitis.
• To emphasize the importance of tailored antimicrobial selection based on causative pathogens and patient factors.

Main Methods:

• Collection of bile for microbial cultures (aerobic and anaerobic) at all opportunities.
• Empirical selection of antimicrobials guided by disease severity, patient history, and local susceptibility patterns (antibiogram).
• Administration of nonsteroidal anti-inflammatory drugs (NSAIDs) for mild cases mimicking biliary colic to prevent inflammation progression.

Main Results:

• Empirical antimicrobial therapy is recommended for acute cholecystitis.
• Tailoring antimicrobial therapy based on identified pathogens and susceptibility testing is essential.
• NSAIDs show efficacy in managing mild inflammatory presentations.

Conclusions:

• Judicious antimicrobial selection, informed by microbiological data and clinical context, is key to managing acute cholecystitis.
• Early intervention with appropriate antimicrobials and NSAIDs (for mild cases) can improve patient outcomes.
• Continuous monitoring of local antibiograms is vital for guiding effective empirical treatment choices.